肺癌
癌症
医学
免疫系统
癌症研究
免疫学
肿瘤科
内科学
作者
Yan Chen,En-Dong Wu,Yifeng Ma,Guangli Shi
标识
DOI:10.7754/clin.lab.2024.240432
摘要
The changed levels of serum NSE, pro-GRP, Cyfra21-1, SCC, and CEA in the lung cancer patients in pre- and post-immunotherapy with ICIs were related to the therapeutic effect and may be used for the response evaluation. The SCLC patients should choose serum NSE, pro-GRP, and CEA for the response evaluation of ICIs immunotherapy, and the NSCLC patients should choose serum Cyfra21-1, SCC, and CEA.
科研通智能强力驱动
Strongly Powered by AbleSci AI